3-Deazaneplanocin A hydrochloride

• CAT Number: I000783
• CAS Number: 120964-45-6
• Molecular Formula: C₁₂H₁₄N₄O₃. HCl
• Molecular Weight: 298.73
• Purity: ≥95%
• Target: iPSC
• Solubility: DMSO: 52 mg/mL, H2O: 52 mg/mL
• Storage: 3 years -20C powder
• IC50: 0.08-0.24 μM (NSCLC cell) [2]
• IUPAC Name: (1S,2R,5R)-5-(4-aminoimidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol;hydrochloride
• InChI: InChI=1S/C12H14N4O3.ClH/c13-12-9-7(1-2-14-12)16(5-15-9)8-3-6(4-17)10(18)11(8)19;/h1-3,5,8,10-11,17-19H,4H2,(H2,13,14);1H
• InChIKey: UNSKMHKAFPRFTI-UHFFFAOYSA-N
• SMILES: C1=CN=C(C2=C1N(C=N2)C3C=C(C(C3O)O)CO)N.Cl

3-Deazaneplanocin A hydrochloride (CAT: I000783) is indeed known for its inhibition of the cellular enhancer of zeste homolog 2 (EZH2) protein, which is a component of the polycomb repressive complex 2 (PRC2) involved in gene silencing through histone methylation. By inhibiting EZH2, DZNep disrupts the methylation of histones and can lead to the reactivation of tumor suppressor genes and inhibition of cancer cell growth. This epigenetic modulation makes DZNep a promising anticancer agent with potential therapeutic applications in various types of cancers.

Reference

1. Avan A, Crea F, Paolicchi E, Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther. 2012 Aug;11(8):1735-46.
2. Kikuchi J, Takashina T, Kinoshita I, Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer. 2012 Nov;78(2):138-43.
3. Sun F, Li J, Yu Q, Loading 3-deazaneplanocin A into pegylated unilamellar liposomes by forming transient phenylboronic acid-drug complex and its pharmacokinetic features in Sprague-Dawley rats. Eur J Pharm Biopharm. 2012 Feb;80(2):323-31.